TY - JOUR
T1 - Insulin-coated gold nanoparticles as a new concept for personalized and adjustable glucose regulation
AU - Shilo, Malka
AU - Berenstein, Peter
AU - Dreifuss, Tamar
AU - Nash, Yuval
AU - Goldsmith, Guy
AU - Kazimirsky, Gila
AU - Motiei, Menachem
AU - Frenkel, Dan
AU - Brodie, Chaya
AU - Popovtzer, Rachela
N1 - Publisher Copyright:
© 2015 The Royal Society of Chemistry.
PY - 2015/12/28
Y1 - 2015/12/28
N2 - Diabetes mellitus is a chronic metabolic disease, characterized by high blood glucose levels, affecting millions of people around the world. Currently, the main treatment for diabetes requires multiple daily injections of insulin and self-monitoring of blood glucose levels, which markedly affect patients' quality of life. In this study we present a novel strategy for controlled and prolonged glucose regulation, based on the administration of insulin-coated gold nanoparticles (INS-GNPs). We show that both intravenous and subcutaneous injection of INS-GNPs into a mouse model of type 1 diabetes decreases blood glucose levels for periods over 3 times longer than free insulin. We further showed that conjugation of insulin to GNPs prevented its rapid degradation by the insulin-degrading-enzyme, and thus allows controlled and adjustable bio-activity. Moreover, we assessed different sizes and concentrations of INS-GNPs, and found that both parameters have a critical effect in vivo, enabling specific adjustment of blood glucose levels. These findings have the potential to improve patient compliance in diabetes mellitus.
AB - Diabetes mellitus is a chronic metabolic disease, characterized by high blood glucose levels, affecting millions of people around the world. Currently, the main treatment for diabetes requires multiple daily injections of insulin and self-monitoring of blood glucose levels, which markedly affect patients' quality of life. In this study we present a novel strategy for controlled and prolonged glucose regulation, based on the administration of insulin-coated gold nanoparticles (INS-GNPs). We show that both intravenous and subcutaneous injection of INS-GNPs into a mouse model of type 1 diabetes decreases blood glucose levels for periods over 3 times longer than free insulin. We further showed that conjugation of insulin to GNPs prevented its rapid degradation by the insulin-degrading-enzyme, and thus allows controlled and adjustable bio-activity. Moreover, we assessed different sizes and concentrations of INS-GNPs, and found that both parameters have a critical effect in vivo, enabling specific adjustment of blood glucose levels. These findings have the potential to improve patient compliance in diabetes mellitus.
UR - http://www.scopus.com/inward/record.url?scp=84949035887&partnerID=8YFLogxK
U2 - 10.1039/c5nr04881h
DO - 10.1039/c5nr04881h
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 26583784
AN - SCOPUS:84949035887
SN - 2040-3364
VL - 7
SP - 20489
EP - 20496
JO - Nanoscale
JF - Nanoscale
IS - 48
ER -